AcouSort AB (publ)

Stockholm Stock Exchange ACOU.ST

AcouSort AB (publ) EBITDA for the year ending December 31, 2023: USD -1.65 M

AcouSort AB (publ) EBITDA is USD -1.65 M for the year ending December 31, 2023, a -34.25% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

AcouSort AB (publ) EBITDA for the year ending December 31, 2022 was USD -1.23 M, a 2.63% change year over year.
AcouSort AB (publ) EBITDA for the year ending December 31, 2021 was USD -1.26 M, a -34.86% change year over year.
AcouSort AB (publ) EBITDA for the year ending December 31, 2020 was USD -935.18 K, a 8.30% change year over year.
AcouSort AB (publ) EBITDA for the year ending December 31, 2019 was USD -1.02 M, a -1.70% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

Stockholm Stock Exchange: ACOU.ST

AcouSort AB (publ)

CEO	Mr. Torsten Freltoft
IPO Date	Dec. 14, 2020
Location	Sweden
Headquarters	Building 406
Employees	17
Sector	Health Care
Industries Biotechnology Medical Instruments

Description

AcouSort AB (publ), a technology company, develops products and solutions for automated preparation of biological samples based on acoustofluidics technology for researchers and life science companies. It offers AcouTrap, a benchtop research instrument for sample preparation of cells, extracellular vesicles, bacteria, and viruses from various media; AcouPlasma, an integrated blood plasma separation module that enables in-line analysis of blood plasma from whole blood samples; and AcouWash, a benchtop research instrument for label-free separation of target cells from various samples. The company was founded in 2010 and is based in Lund, Sweden.

Key trends

Past 5 years